---
document_datetime: 2025-12-02 05:53:19
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/ertapenem-sun.html
document_name: ertapenem-sun.html
version: success
processing_time: 0.1052366
conversion_datetime: 2025-12-24 21:42:54.436986
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Ertapenem SUN

[RSS](/en/individual-human-medicine.xml/67577)

##### Authorised

This medicine is authorised for use in the European Union

ertapenem Medicine Human Authorised

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [News on Ertapenem SUN](#news-on)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

Ertapenem SUN is an antibiotic. It is used in adults and children over 3 months of age to treat:

- infections within the abdomen;
- community-acquired pneumonia (infection of the lungs caught away from hospital);
- gynaecological infections;
- foot infections in diabetes patients.

Ertapenem SUN is also used in adults to prevent infection after colorectal surgery (surgery in the lower part of the bowel, including the rectum).

Ertapenem SUN is used when the bacteria that cause the infection are likely to be killed by the antibiotic. Before using Ertapenem SUN, doctors should consider official guidance on the appropriate use of antibiotics.

Ertapenem SUN is a 'generic medicine'. This means that Ertapenem SUN contains the same active substance and works in the same way as a 'reference medicine' already authorised in the EU called Invanz. For more information on generic medicines, see the question-and-answer document [here](https://www.ema.europa.eu/en/documents/medicine-qa/questions-answers-generic-medicines_en.pdf) .

Ertapenem SUN contains the active substance ertapenem.

Expand section

Collapse section

## How is Ertapenem SUN used?

Ertapenem SUN is available as a vial containing a powder which is dissolved before use to make up a solution for infusion (drip) into a vein. It is infused over 30 minutes. The medicine can only be obtained with a prescription.

Ertapenem SUN is given at a dose of 1 g once a day in adults and adolescents. For younger patients (3 months to 12 years), a dose of 15 mg per kilogram body weight is given twice a day, up to a total of 1 g per day. Treatment with Ertapenem SUN lasts between 3 and 14 days, depending on the type and the severity of the infection. Once the infection has improved, treatment can be switched to an antibiotic that can be given by mouth.

For preventing infection after colorectal surgery in adults, a single dose of Ertapenem SUN is given within 1 hour before the operation.

For more information about using Ertapenem SUN, see the package leaflet or contact your doctor or pharmacist.

## How does Ertapenem SUN work?

The active substance in Ertapenem SUN, ertapenem, belongs to the group of antibiotics known as 'carbapenems'. It attaches to certain proteins on the bacteria cells. This upsets the essential functions that keep these cells alive, and so kills the bacteria. Ertapenem SUN can work on a range of different bacteria.

## How has Ertapenem SUN been studied?

Studies on the benefits and risks of the active substance in the authorised use have already been carried out with the reference medicine, Invanz, and do not need to be repeated for Ertapenem SUN.

As for every medicine, the company provided studies on the quality of Ertapenem SUN. There was no need for 'bioequivalence' studies to investigate whether Ertapenem SUN is absorbed similarly to the reference medicine to produce the same level of the active substance in the blood. This is because Ertapenem SUN is given by infusion into a vein, so the active substance is delivered straight into the bloodstream.

## What are the benefits and risks of Ertapenem SUN?

Because Ertapenem SUN is a generic medicine and is bioequivalent to the reference medicine, its benefits and risks are taken as being the same as the reference medicine's.

## Why is Ertapenem SUN authorised in the EU?

The European Medicines Agency concluded that, in accordance with EU requirements, Ertapenem SUN has been shown to have comparable quality and to be bioequivalent to Invanz. Therefore, the Agency's view was that, as for Invanz, the benefits of Ertapenem SUN outweigh the identified risks and it can be authorised for use in the EU.

## What measures are being taken to ensure the safe and effective use of Ertapenem SUN?

Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Ertapenem SUN have been included in the summary of product characteristics and the package leaflet.

As for all medicines, data on the use of Ertapenem SUN are continuously monitored. Suspected side effects reported with Ertapenem SUN are carefully evaluated and any necessary action taken to protect patients.

## Other information about Ertapenem SUN

Ertapenem SUN received a marketing authorisation valid throughout the EU on 15 July 2022

This overview was last updated in 09-2022

Ertapenem SUN : EPAR - Medicine Overview

Reference Number: EMEA/H/C/005815

English (EN) (167.1 KB - PDF)

**First published:** 30/09/2022

[View](/en/documents/overview/ertapenem-sun-epar-medicine-overview_en.pdf)

[Other languages (22)](#file-language-dropdown-138)

български (BG) (191.04 KB - PDF)

**First published:**

30/09/2022

[View](/bg/documents/overview/ertapenem-sun-epar-medicine-overview_bg.pdf)

español (ES) (168.27 KB - PDF)

**First published:**

30/09/2022

[View](/es/documents/overview/ertapenem-sun-epar-medicine-overview_es.pdf)

čeština (CS) (188.15 KB - PDF)

**First published:**

30/09/2022

[View](/cs/documents/overview/ertapenem-sun-epar-medicine-overview_cs.pdf)

dansk (DA) (167 KB - PDF)

**First published:**

30/09/2022

[View](/da/documents/overview/ertapenem-sun-epar-medicine-overview_da.pdf)

Deutsch (DE) (171.54 KB - PDF)

**First published:**

30/09/2022

[View](/de/documents/overview/ertapenem-sun-epar-medicine-overview_de.pdf)

eesti keel (ET) (156.09 KB - PDF)

**First published:**

30/09/2022

[View](/et/documents/overview/ertapenem-sun-epar-medicine-overview_et.pdf)

ελληνικά (EL) (191.99 KB - PDF)

**First published:**

30/09/2022

[View](/el/documents/overview/ertapenem-sun-epar-medicine-overview_el.pdf)

français (FR) (169.34 KB - PDF)

**First published:**

30/09/2022

[View](/fr/documents/overview/ertapenem-sun-epar-medicine-overview_fr.pdf)

hrvatski (HR) (185.66 KB - PDF)

**First published:**

30/09/2022

[View](/hr/documents/overview/ertapenem-sun-epar-medicine-overview_hr.pdf)

italiano (IT) (167.09 KB - PDF)

**First published:**

30/09/2022

[View](/it/documents/overview/ertapenem-sun-epar-medicine-overview_it.pdf)

latviešu valoda (LV) (205.09 KB - PDF)

**First published:**

30/09/2022

[View](/lv/documents/overview/ertapenem-sun-epar-medicine-overview_lv.pdf)

lietuvių kalba (LT) (187.84 KB - PDF)

**First published:**

30/09/2022

[View](/lt/documents/overview/ertapenem-sun-epar-medicine-overview_lt.pdf)

magyar (HU) (190.26 KB - PDF)

**First published:**

30/09/2022

[View](/hu/documents/overview/ertapenem-sun-epar-medicine-overview_hu.pdf)

Malti (MT) (192.54 KB - PDF)

**First published:**

30/09/2022

[View](/mt/documents/overview/ertapenem-sun-epar-medicine-overview_mt.pdf)

Nederlands (NL) (167.69 KB - PDF)

**First published:**

30/09/2022

[View](/nl/documents/overview/ertapenem-sun-epar-medicine-overview_nl.pdf)

polski (PL) (190.91 KB - PDF)

**First published:**

30/09/2022

[View](/pl/documents/overview/ertapenem-sun-epar-medicine-overview_pl.pdf)

português (PT) (168.85 KB - PDF)

**First published:**

30/09/2022

[View](/pt/documents/overview/ertapenem-sun-epar-medicine-overview_pt.pdf)

română (RO) (187.84 KB - PDF)

**First published:**

30/09/2022

[View](/ro/documents/overview/ertapenem-sun-epar-medicine-overview_ro.pdf)

slovenčina (SK) (187.27 KB - PDF)

**First published:**

30/09/2022

[View](/sk/documents/overview/ertapenem-sun-epar-medicine-overview_sk.pdf)

slovenščina (SL) (186.54 KB - PDF)

**First published:**

30/09/2022

[View](/sl/documents/overview/ertapenem-sun-epar-medicine-overview_sl.pdf)

Suomi (FI) (166.36 KB - PDF)

**First published:**

30/09/2022

[View](/fi/documents/overview/ertapenem-sun-epar-medicine-overview_fi.pdf)

svenska (SV) (166.39 KB - PDF)

**First published:**

30/09/2022

[View](/sv/documents/overview/ertapenem-sun-epar-medicine-overview_sv.pdf)

Ertapenem SUN : EPAR - Risk Management Plan summary

English (EN) (212.12 KB - PDF)

**First published:** 30/09/2022

[View](/en/documents/rmp-summary/ertapenem-sun-epar-risk-management-plan-summary_en.pdf)

## Product information

Ertapenem SUN : EPAR - Product Information

English (EN) (340.08 KB - PDF)

**First published:** 30/09/2022

**Last updated:** 03/04/2024

[View](/en/documents/product-information/ertapenem-sun-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-622)

български (BG) (447.38 KB - PDF)

**First published:**

30/09/2022

**Last updated:**

03/04/2024

[View](/bg/documents/product-information/ertapenem-sun-epar-product-information_bg.pdf)

español (ES) (351.37 KB - PDF)

**First published:**

30/09/2022

**Last updated:**

03/04/2024

[View](/es/documents/product-information/ertapenem-sun-epar-product-information_es.pdf)

čeština (CS) (412.13 KB - PDF)

**First published:**

30/09/2022

**Last updated:**

03/04/2024

[View](/cs/documents/product-information/ertapenem-sun-epar-product-information_cs.pdf)

dansk (DA) (345.76 KB - PDF)

**First published:**

30/09/2022

**Last updated:**

03/04/2024

[View](/da/documents/product-information/ertapenem-sun-epar-product-information_da.pdf)

Deutsch (DE) (358.29 KB - PDF)

**First published:**

30/09/2022

**Last updated:**

03/04/2024

[View](/de/documents/product-information/ertapenem-sun-epar-product-information_de.pdf)

eesti keel (ET) (323.25 KB - PDF)

**First published:**

30/09/2022

**Last updated:**

03/04/2024

[View](/et/documents/product-information/ertapenem-sun-epar-product-information_et.pdf)

ελληνικά (EL) (474.97 KB - PDF)

**First published:**

30/09/2022

**Last updated:**

03/04/2024

[View](/el/documents/product-information/ertapenem-sun-epar-product-information_el.pdf)

français (FR) (340.53 KB - PDF)

**First published:**

30/09/2022

**Last updated:**

03/04/2024

[View](/fr/documents/product-information/ertapenem-sun-epar-product-information_fr.pdf)

hrvatski (HR) (370.12 KB - PDF)

**First published:**

30/09/2022

**Last updated:**

03/04/2024

[View](/hr/documents/product-information/ertapenem-sun-epar-product-information_hr.pdf)

íslenska (IS) (350.01 KB - PDF)

**First published:**

30/09/2022

**Last updated:**

03/04/2024

[View](/is/documents/product-information/ertapenem-sun-epar-product-information_is.pdf)

italiano (IT) (346.22 KB - PDF)

**First published:**

30/09/2022

**Last updated:**

03/04/2024

[View](/it/documents/product-information/ertapenem-sun-epar-product-information_it.pdf)

latviešu valoda (LV) (413.33 KB - PDF)

**First published:**

30/09/2022

**Last updated:**

03/04/2024

[View](/lv/documents/product-information/ertapenem-sun-epar-product-information_lv.pdf)

lietuvių kalba (LT) (393.89 KB - PDF)

**First published:**

30/09/2022

**Last updated:**

03/04/2024

[View](/lt/documents/product-information/ertapenem-sun-epar-product-information_lt.pdf)

magyar (HU) (384.09 KB - PDF)

**First published:**

30/09/2022

**Last updated:**

03/04/2024

[View](/hu/documents/product-information/ertapenem-sun-epar-product-information_hu.pdf)

Malti (MT) (567.14 KB - PDF)

**First published:**

30/09/2022

**Last updated:**

03/04/2024

[View](/mt/documents/product-information/ertapenem-sun-epar-product-information_mt.pdf)

Nederlands (NL) (352.94 KB - PDF)

**First published:**

30/09/2022

**Last updated:**

03/04/2024

[View](/nl/documents/product-information/ertapenem-sun-epar-product-information_nl.pdf)

norsk (NO) (355.47 KB - PDF)

**First published:**

30/09/2022

**Last updated:**

03/04/2024

[View](/no/documents/product-information/ertapenem-sun-epar-product-information_no.pdf)

polski (PL) (423.55 KB - PDF)

**First published:**

30/09/2022

**Last updated:**

03/04/2024

[View](/pl/documents/product-information/ertapenem-sun-epar-product-information_pl.pdf)

português (PT) (354.78 KB - PDF)

**First published:**

30/09/2022

**Last updated:**

03/04/2024

[View](/pt/documents/product-information/ertapenem-sun-epar-product-information_pt.pdf)

română (RO) (410.11 KB - PDF)

**First published:**

30/09/2022

**Last updated:**

03/04/2024

[View](/ro/documents/product-information/ertapenem-sun-epar-product-information_ro.pdf)

slovenčina (SK) (383.41 KB - PDF)

**First published:**

30/09/2022

**Last updated:**

03/04/2024

[View](/sk/documents/product-information/ertapenem-sun-epar-product-information_sk.pdf)

slovenščina (SL) (381.99 KB - PDF)

**First published:**

30/09/2022

**Last updated:**

03/04/2024

[View](/sl/documents/product-information/ertapenem-sun-epar-product-information_sl.pdf)

Suomi (FI) (341.52 KB - PDF)

**First published:**

30/09/2022

**Last updated:**

03/04/2024

[View](/fi/documents/product-information/ertapenem-sun-epar-product-information_fi.pdf)

svenska (SV) (354.83 KB - PDF)

**First published:**

30/09/2022

**Last updated:**

03/04/2024

[View](/sv/documents/product-information/ertapenem-sun-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** N/0003 02/04/2024

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Ertapenem SUN : EPAR - All Authorised Presentations

English (EN) (40.75 KB - PDF)

**First published:** 30/09/2022

[View](/en/documents/all-authorised-presentations/ertapenem-sun-epar-all-authorised-presentations_en.pdf)

[Other languages (24)](#file-language-dropdown-923)

български (BG) (54.54 KB - PDF)

**First published:**

30/09/2022

[View](/bg/documents/all-authorised-presentations/ertapenem-sun-epar-all-authorised-presentations_bg.pdf)

español (ES) (40.88 KB - PDF)

**First published:**

30/09/2022

[View](/es/documents/all-authorised-presentations/ertapenem-sun-epar-all-authorised-presentations_es.pdf)

čeština (CS) (59 KB - PDF)

**First published:**

30/09/2022

[View](/cs/documents/all-authorised-presentations/ertapenem-sun-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (42.45 KB - PDF)

**First published:**

30/09/2022

[View](/da/documents/all-authorised-presentations/ertapenem-sun-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (42.99 KB - PDF)

**First published:**

30/09/2022

[View](/de/documents/all-authorised-presentations/ertapenem-sun-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (40.4 KB - PDF)

**First published:**

30/09/2022

[View](/et/documents/all-authorised-presentations/ertapenem-sun-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (57.69 KB - PDF)

**First published:**

30/09/2022

[View](/el/documents/all-authorised-presentations/ertapenem-sun-epar-all-authorised-presentations_el.pdf)

français (FR) (41.03 KB - PDF)

**First published:**

30/09/2022

[View](/fr/documents/all-authorised-presentations/ertapenem-sun-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (57.79 KB - PDF)

**First published:**

30/09/2022

[View](/hr/documents/all-authorised-presentations/ertapenem-sun-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (42.91 KB - PDF)

**First published:**

30/09/2022

[View](/is/documents/all-authorised-presentations/ertapenem-sun-epar-all-authorised-presentations_is.pdf)

italiano (IT) (40.68 KB - PDF)

**First published:**

30/09/2022

[View](/it/documents/all-authorised-presentations/ertapenem-sun-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (59.83 KB - PDF)

**First published:**

30/09/2022

[View](/lv/documents/all-authorised-presentations/ertapenem-sun-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (59.18 KB - PDF)

**First published:**

30/09/2022

[View](/lt/documents/all-authorised-presentations/ertapenem-sun-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (49.63 KB - PDF)

**First published:**

30/09/2022

[View](/hu/documents/all-authorised-presentations/ertapenem-sun-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (58.59 KB - PDF)

**First published:**

30/09/2022

[View](/mt/documents/all-authorised-presentations/ertapenem-sun-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (41.64 KB - PDF)

**First published:**

30/09/2022

[View](/nl/documents/all-authorised-presentations/ertapenem-sun-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (41.82 KB - PDF)

**First published:**

30/09/2022

[View](/no/documents/all-authorised-presentations/ertapenem-sun-epar-all-authorised-presentations_no.pdf)

polski (PL) (62.37 KB - PDF)

**First published:**

30/09/2022

[View](/pl/documents/all-authorised-presentations/ertapenem-sun-epar-all-authorised-presentations_pl.pdf)

português (PT) (47.93 KB - PDF)

**First published:**

30/09/2022

[View](/pt/documents/all-authorised-presentations/ertapenem-sun-epar-all-authorised-presentations_pt.pdf)

română (RO) (59 KB - PDF)

**First published:**

30/09/2022

[View](/ro/documents/all-authorised-presentations/ertapenem-sun-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (57.73 KB - PDF)

**First published:**

30/09/2022

[View](/sk/documents/all-authorised-presentations/ertapenem-sun-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (49.61 KB - PDF)

**First published:**

30/09/2022

[View](/sl/documents/all-authorised-presentations/ertapenem-sun-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (40.28 KB - PDF)

**First published:**

30/09/2022

[View](/fi/documents/all-authorised-presentations/ertapenem-sun-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (39.47 KB - PDF)

**First published:**

30/09/2022

[View](/sv/documents/all-authorised-presentations/ertapenem-sun-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Ertapenem SUN Active substance ertapenem sodium International non-proprietary name (INN) or common name ertapenem Therapeutic area (MeSH) Bacterial Infections

### Pharmacotherapeutic group

ertapenem

### Therapeutic indication

**Treatment**

- Intra-abdominal infections
- Community acquired pneumonia
- Acute gynaecological infections
- Diabetic foot infections of the skin and soft tissue (see section 4.4)

**Prevention** Ertapenem SUN is indicated in adults for the prophylaxis of surgical site infection following elective colorectal surgery (see section 4.4).

Consideration should be given to official guidance on the appropriate use of antibacterial agents.

## Authorisation details

EMA product number EMEA/H/C/005815

Generic

This is a generic medicine, which is developed to be the same as a medicine that has already been authorised, called the reference medicine. A generic medicine contains the same active substance(s) as the reference medicine, and is used at the same dose(s) to treat the same disease(s). For more information, see [Generic and hybrid medicines](/node/69107) .

Marketing authorisation holder

SUN Pharmaceutical Industries (Europe) B.V.

Polarisavenue 87 2132JH Hoofddorp The Netherlands

Opinion adopted 19/05/2022 Marketing authorisation issued 15/07/2022 Revision 2

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Ertapenem SUN : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (102.07 KB - PDF)

**First published:** 19/03/2024

**Last updated:** 03/04/2024

[View](/en/documents/procedural-steps-after/ertapenem-sun-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf)

## Initial marketing authorisation documents

Ertapenem SUN : EPAR - Public assessment report

Adopted

Reference Number: EMA/569175/2022

English (EN) (419.72 KB - PDF)

**First published:** 21/11/2022

[View](/en/documents/assessment-report/ertapenem-sun-epar-public-assessment-report_en.pdf)

CHMP summary of positive opinion for Ertapenem SUN

Adopted

Reference Number: EMA/CHMP/266696/2022

English (EN) (100.47 KB - PDF)

**First published:** 20/05/2022

[View](/en/documents/smop-initial/chmp-summary-positive-opinion-ertapenem-sun_en.pdf)

#### News on Ertapenem SUN

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 16-19 May 2022](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-16-19-may-2022) 20/05/2022

**This page was last updated on** 03/04/2024

## Share this page

[Back to top](#main-content)